Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients

Many doctors hoped that adding a stem cell transplant would give younger lymphoma patients a better chance. This large trial tested that hope. It involved 870 patients aged 18 to 65 years with untreated mantle cell lymphoma. These patients were treated at 165 centers across 13 European countries and Israel. The goal was to see if adding the transplant to a drug called ibrutinib helped them live longer without the disease coming back. The main measure was failure-free survival, which means staying alive without the cancer returning or needing new treatment. The results were clear. Adding the transplant did not make patients do better than those who just took the ibrutinib drugs. In fact, the group with the transplant had more serious side effects. They faced more blood disorders and infections. The study followed patients for nearly five years. Even at the four-year mark, the added transplant did not change the outcome. Patients who got the transplant had a higher risk of dying from infections. This means the extra treatment added harm without adding life. The study confirms that for this specific group, the standard drug plan is enough. There is no need for the risky transplant step right now. This finding helps doctors decide on the best path for their patients without unnecessary risk.